BR100 Increased By (1.14%)
BR30 Increased By (1.36%)
KSE100 Increased By (0.9%)
KSE30 Increased By (0.94%)
BECO 5.75 Increased By ▲ 0.16 (2.86%)
BML 63.00 Increased By ▲ 1.97 (3.23%)
BOP 33.62 Increased By ▲ 0.37 (1.11%)
CNERGY 8.25 Increased By ▲ 0.20 (2.48%)
DCL 11.48 Increased By ▲ 0.18 (1.59%)
FCCL 53.01 Increased By ▲ 0.08 (0.15%)
FCSC 5.59 Increased By ▲ 0.25 (4.68%)
FFL 17.81 Increased By ▲ 0.20 (1.14%)
FNEL 1.31 No Change ▼ 0.00 (0%)
HUMNL 11.15 Increased By ▲ 0.03 (0.27%)
KEL 7.99 Increased By ▲ 0.10 (1.27%)
KOSM 5.50 Increased By ▲ 0.17 (3.19%)
MLCF 86.33 Increased By ▲ 0.98 (1.15%)
NBP 184.70 Increased By ▲ 3.41 (1.88%)
PACE 12.22 Increased By ▲ 0.69 (5.98%)
PAEL 40.45 Increased By ▲ 1.04 (2.64%)
PIAHCLA 25.75 Increased By ▲ 0.12 (0.47%)
PIBTL 17.33 Increased By ▲ 0.18 (1.05%)
PPL 226.00 Increased By ▲ 1.18 (0.52%)
PRL 34.39 Increased By ▲ 0.21 (0.61%)
PTC 65.80 Increased By ▲ 0.72 (1.11%)
SEARL 90.64 Increased By ▲ 1.04 (1.16%)
SSGC 26.86 Increased By ▲ 0.55 (2.09%)
TELE 8.60 Increased By ▲ 0.22 (2.63%)
THCCL 70.29 Increased By ▲ 0.95 (1.37%)
TPLP 11.31 Increased By ▲ 1.03 (10.02%)
TREET 24.53 Increased By ▲ 0.33 (1.36%)
TRG 71.86 Increased By ▲ 2.32 (3.34%)
WAVES 11.48 Increased By ▲ 0.45 (4.08%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
Business & Finance

One in 10 medical products in developing countries is substandard or falsified: WHO

ISLAMABAD: An estimated one in 10 medical products circulating in low- and middle-income countries is either substan
Published January 26, 2018 Updated January 26, 2018 08:07pm

ISLAMABAD: An estimated one in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from WHO.

The research report which was launched by World Health Organization (WHO) said people are taking medicines that fail to treat or prevent disease. Not only is this a waste of money for individuals and health systems that purchase these products, but substandard or falsified medical products can cause serious illness or even death.

“Substandard and falsified medicines particularly affect the most vulnerable communities,” says Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Imagine a mother who gives up food or other basic needs to pay for her child’s treatment, unaware that the medicines are substandard or falsified, and then that treatment causes her child to die. This is unacceptable. countries have agreed on measures at the global level – it is time to translate them into tangible action.”

Since 2013, WHO has received 1500 reports of cases of substandard or falsified products. Of these, antimalarials and antibiotics are the most commonly reported. Most of the reports (42%) come from the WHO African Region, 21% from the WHO Region of the Americas, and 21% from the WHO European Region.

This is likely just a small fraction of the total problem and many cases may be going unreported. For example, only 8% of reports of substandard or falsified products to WHO came from the WHO Western Pacific Region, 6% from the WHO Eastern Mediterranean Region, and just 2% from the WHO South-East Asia Region, the report said.

“Many of these products, like antibiotics, are vital for people’s survival and wellbeing,” says Dr Mariângela Simão, Assistant Director-General for Access to Medicines, Vaccines and Pharmaceuticals at WHO.

“Substandard or falsified medicines not only have a tragic impact on individual patients and their families, but also are a threat to antimicrobial resistance, adding to the worrying trend of medicines losing their power to treat”.

Prior to 2013, there was no global reporting of this information. Since WHO established the Global Surveillance and Monitoring System for substandard and falsified products, many countries are now active in reporting suspicious medicines, vaccines and medical devices.

WHO has trained 550 regulators from 141 countries to detect and respond to this issue. As more people are trained, more cases are reported to WHO.

WHO has received reports of substandard or falsified medical products ranging from cancer treatment to normal diseases. They are not confined to high-value medicines or well-known brand names and are split almost evenly between generic and patented products.

Copyright APP (Associated Press of Pakistan), 2018

Comments

Comments are closed for this article.